Sun Pharma Advanced Research Co. Ltd. (IN:SPARC)
:SPARC
Top Page
Sun Pharma Advanced Research Co. Ltd.
(SPARC)
Select Model
Select Model
Rating:41Neutral
Price Target:
₹115.00
▼(-15.25% Downside)
Action:ReiteratedDate:03/28/26
The score is held down primarily by very weak financial performance (losses, negative cash flows, and negative equity). Technicals also lean bearish with the stock below key longer-term moving averages and a negative MACD. Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Licensing / Partnership Monetization Model
SPARC’s primary monetization via out-licensing, milestones and royalties creates a capital-efficient pathway to convert R&D into cash. Durable partner-funded development and milestone payouts can de-risk spend, provide non-linear upside and preserve equity capital as programs mature.
Negative Factors
Negative Stockholders' Equity & High Leverage
Negative equity and elevated leverage are persistent structural liabilities that constrain financial flexibility. They increase refinancing and covenant risk, can elevate funding costs, and may deter counterparties or limit the company’s ability to pursue opportunistic deals or strategic investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Licensing / Partnership Monetization Model
SPARC’s primary monetization via out-licensing, milestones and royalties creates a capital-efficient pathway to convert R&D into cash. Durable partner-funded development and milestone payouts can de-risk spend, provide non-linear upside and preserve equity capital as programs mature.
Read all positive factors
Sun Pharma Advanced Research Co. Ltd. (SPARC) vs. iShares MSCI India ETF (INDA)
Market Cap
₹37.19B
Dividend YieldN/A
Average Volume (3M)24.00K
Price to Earnings (P/E)―
Beta (1Y)1.57
Revenue Growth-0.82%
EPS Growth34.67%
CountryIN
Employees409
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-2.48
Shares Outstanding324,521,580
10 Day Avg. Volume27,089
30 Day Avg. Volume24,005
Financial Highlights & Ratios
PEG Ratio1.20
Price to Book (P/B)-21.89
Price to Sales (P/S)66.17
P/FCF Ratio-12.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Sun Pharma Advanced Research Co. Ltd. Business Overview & Revenue Model
Company Description
Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical and biological entities, and reformulated products...
How the Company Makes Money
SPARC makes money primarily by monetizing the drug candidates and technologies it develops. Key revenue streams typically include: (1) Out-licensing and partnering income: SPARC enters licensing or collaboration agreements with other pharmaceutica...
Sun Pharma Advanced Research Co. Ltd. Financial Statement Overview
Summary
Income Statement
30
Negative
Balance Sheet
25
Negative
Cash Flow
35
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 596.00M | 717.70M | 755.45M | 2.39B | 1.37B | 2.53B |
| Gross Profit | -12.40M | 486.50M | -1.24B | 821.21M | 105.52M | 465.55M |
| EBITDA | -2.35B | -3.23B | -3.73B | -2.03B | -1.80B | -1.30B |
| Net Income | -2.67B | -3.43B | -3.87B | -2.23B | -2.03B | -1.51B |
Balance Sheet | ||||||
| Total Assets | 3.22B | 3.36B | 5.15B | 8.30B | 2.80B | 2.30B |
| Cash, Cash Equivalents and Short-Term Investments | 30.00M | 19.60M | 1.57B | 4.07B | 128.89M | 157.30M |
| Total Debt | 4.17B | 2.69B | 611.51M | 156.70M | 792.14M | 2.36B |
| Total Liabilities | 6.67B | 5.52B | 3.89B | 3.17B | 2.49B | 3.98B |
| Stockholders Equity | -3.45B | -2.17B | 1.26B | 5.13B | 312.26M | -1.68B |
Cash Flow | ||||||
| Free Cash Flow | -1.39B | -3.71B | -4.56B | -845.10M | -2.41B | -1.58B |
| Operating Cash Flow | -1.16B | -3.60B | -4.29B | -691.20M | -2.08B | -1.52B |
| Investing Cash Flow | -231.00M | 1.58B | 3.92B | -5.48B | -291.67M | 15.62M |
| Financing Cash Flow | 1.38B | 1.99B | 424.05M | 6.17B | 2.29B | 1.59B |
Sun Pharma Advanced Research Co. Ltd. Technical Analysis
Negative
135.70
Price Trends
127.65
Negative
132.09
Negative
139.45
Negative
Market Momentum
-2.93
Negative
48.40
Neutral
53.91
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SPARC, the sentiment is Negative. The current price of 135.7 is above the 20-day moving average (MA) of 120.78, above the 50-day MA of 127.65, and below the 200-day MA of 139.45, indicating a bearish trend. The MACD of -2.93 indicates Negative momentum. The RSI at 48.40 is Neutral, neither overbought nor oversold. The STOCH value of 53.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:SPARC.
Sun Pharma Advanced Research Co. Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹30.60B | 43.39 | ― | 0.85% | ― | ― | |
69 Neutral | ₹55.67B | 61.22 | ― | 0.68% | 22.36% | 52.00% | |
68 Neutral | ₹45.48B | 30.45 | ― | 0.13% | 14.35% | 15.79% | |
57 Neutral | ₹29.15B | 23.17 | ― | 0.24% | 4.08% | 31.52% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | ₹30.81B | -9.14 | ― | ― | ― | ― | |
41 Neutral | ₹37.19B | -13.56 | ― | ― | -0.82% | 34.67% |
* Healthcare Sector Average
IN:SPARC
Sun Pharma Advanced Research Co. Ltd.
114.60
-31.75
-21.69%
IN:AARTIDRUGS
Aarti Drugs Limited
319.40
-18.59
-5.50%
IN:RPGLIFE
RPG Life Sciences Limited
1,850.15
-383.37
-17.16%
IN:SUPRIYA
Supriya Lifescience Limited
565.10
-166.14
-22.72%
IN:SUVEN
Suven Life Sciences Limited
132.85
10.90
8.94%
IN:THYROCARE
Thyrocare Technologies Ltd
349.75
114.54
48.70%
Sun Pharma Advanced Research Co. Ltd. Corporate Events
SPARC EGM Clears Path for Promoter-Backed Preferential Issue
Feb 9, 2026
Sun Pharma Advanced Research Company Ltd. informed exchanges about the conduct of its Extraordinary General Meeting on 9 February 2026, held via video conferencing with full board attendance and requisite quorum. Shareholders were provided remote ...
SPARC Board Clears Q3 and Nine-Month FY26 Results After Clean Auditor Review
Feb 9, 2026
Sun Pharma Advanced Research Company Limited announced that its board has approved the unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025, at a meeting held on February 9, 2026. Th...
Exchange Seeks Clarification After Surge in Sun Pharma Advanced Research Trading Volume
Feb 1, 2026
Trading in Sun Pharma Advanced Research Company Limited shares has seen a significant increase in volume, prompting the stock exchange to seek clarification from the company. The exchange has requested updated, relevant information to ensure marke...
Sun Pharma Advanced Research Publishes EGM Notice in Line with SEBI Disclosure Norms
Jan 17, 2026
Sun Pharma Advanced Research Company Limited has notified stock exchanges that it has published public notices convening an Extra Ordinary General Meeting (EGM) of shareholders through advertisements in multiple editions of the Financial Express i...
SPARC Calls February EGM to Approve Preferential Issue of Convertible Warrants
Jan 16, 2026
Sun Pharma Advanced Research Company Limited has called an extraordinary general meeting (EGM) of its shareholders on 9 February 2026, to be held via video conferencing, with remote e-voting scheduled between 5 and 8 February 2026. The key agenda ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.